Asset Management One Co. Ltd. Boosts Holdings in DexCom, Inc. (NASDAQ:DXCM)

Asset Management One Co. Ltd. increased its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 10.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 235,474 shares of the medical device company's stock after buying an additional 22,268 shares during the period. Asset Management One Co. Ltd. owned 0.06% of DexCom worth $15,786,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of DexCom in the second quarter valued at $25,000. Sachetta LLC increased its position in shares of DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company's stock worth $27,000 after acquiring an additional 171 shares during the period. Crewe Advisors LLC bought a new stake in shares of DexCom during the first quarter valued at approximately $29,000. Riverview Trust Co boosted its holdings in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after purchasing an additional 232 shares during the period. Finally, DT Investment Partners LLC lifted its holdings in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after buying an additional 315 shares during the period. Institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

DXCM has been the subject of several recent research reports. Oppenheimer reduced their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Stifel Nicolaus increased their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, August 23rd. Piper Sandler reaffirmed an "overweight" rating and issued a $90.00 price target on shares of DexCom in a report on Monday, August 26th. BTIG Research reduced their target price on DexCom from $156.00 to $120.00 and set a "buy" rating for the company in a research note on Friday, July 26th. Finally, Barclays reduced their price objective on DexCom from $138.00 to $113.00 and set an "equal weight" rating for the company in a research note on Monday, July 29th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $104.59.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by company insiders.

DexCom Stock Down 1.0 %

DXCM stock traded down $0.69 during trading on Wednesday, hitting $68.31. 3,362,107 shares of the company's stock were exchanged, compared to its average volume of 3,898,759. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The business has a 50-day moving average price of $69.70 and a two-hundred day moving average price of $94.48. The stock has a market capitalization of $26.68 billion, a price-to-earnings ratio of 41.32, a PEG ratio of 2.16 and a beta of 1.17.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.